CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...